The legacy success of sildenafil has undeniably shaped the healthcare landscape. However, investing in companies heavily dependent on biosimilars and the waning patent rights surrounding this iconic https://ilovebookmark.com/story21235261/the-blue-pill-and-pharmaceutical-companies-a-uncertain-opportunity